Ozmosi @OzmosiHealth Twitter profile

Last Seen Profiles

@MissGeeta0

@stw_pdg

@Muhamad_Almatar

@hey_mollly

@LIZZIEKlM

@ufdiabetes

@Popjustice

@discordfora

@BerdinaCarla

@PhilEdwardsFH

@BitDigestdaily

@robikaran

@_NaNaiLady

@Blanchier27

@TauncangKas

@srap12701739

@dhfvudh

@GauntlettR31395

@BrettKollmann

@erinaman_kyoto

@prince_of_fakes

@bokeplokalmalam

@m4rri4nne

@StalkingVi96051

@IMGAcademy

@BinorRaja

@atia050

@Greenon_AD

@marcelin_mcil

@MedLabNigeria

@mofu061

@PaulErikVeel

@8w_xfggi

@just__myan

@niskaelara

@jotslo

Ozmosi

@OzmosiHealth

11 months

$AGIO: Promising potential for anemia treatment. $ALZN: FDA approves Alzamend Neuro's lithium study. $CYBN: Cybin's depression study findings, plans. Briefing. $INAB: IN8bio's INB-200 boosts survival in glioblastoma. $AZN: FDA approves FoundationOne CDx for breast cancer.

0

10

Ozmosi

@OzmosiHealth

11 months

$CYBN Cybin will hold a CYB003 depression study review and R&D briefing on Nov 30, 2023, in NYC. More Info: $XBI $IBB $XPH $PPH

0

1

3

Ozmosi

@OzmosiHealth

1 year

$SAVA Cassava Sciences reveals research confirming how Simufilam, a potential Alzheimer's drug, works. More Info: $XBI $IBB $XPH $PPH

2

8

41

Ozmosi

@OzmosiHealth

1 year

$SAVA Cassava Sciences finishes recruiting patients for crucial Phase 3 study on Alzheimer's, testing oral Simufilam as a potential treatment. More Info: $XBI $IBB $XPH $PPH

0

4

36

Ozmosi

@OzmosiHealth

6 months

$OCGN Ocugen, Inc. Receives Positive Scientific Advice from European Medicines Agency regarding Approval Process for OCU400 Gene Therapy for Retinitis Pigmentosa. More Info: $XBI $IBB $XPH $PPH

0

13

34

Ozmosi

@OzmosiHealth

6 months

$OCGN Ocugen completes dosing of subjects with Geographic Atrophy in Phase 1/2 ArMaDa trial of OCU410 gene therapy modifier. More Info: $XBI $IBB $XPH $PPH

0

10

32

Ozmosi

@OzmosiHealth

10 days

$SAVA Cassava Sciences finishes safety check for oral Simufilam in Phase 3 trials. More Info: $XBI $IBB $XPH $PPH

0

7

29

Ozmosi

@OzmosiHealth

1 year

$OCGN Preliminary trial results for Ocu400, a modifier gene therapy for retinitis pigmentosa and Leber Congenital Amaurosis, show promise. More Info: $XBI $IBB $XPH $PPH

Ozmosi | OCU-400 Drug Profile

OCU400 (AAV-NR2E3) is a novel gene therapy product candidate with the potential to be broadly effective in restoring retinal integrity and function across a range of genetically diverse inherited...

pryzm.ozmosi.com

1

5

21

Ozmosi

@OzmosiHealth

4 months

$OCGN Ocugen, Inc. begins Phase 3 trial for OCU400, the first gene therapy for retinitis pigmentosa with broad indication. More Info: $XBI $IBB $XPH $PPH

0

8

19

Ozmosi

@OzmosiHealth

5 months

$OCGN Ocugen to present Phase 1/2 data on OCU400 gene therapy at Retinal Cell and Gene Therapy Innovation Summit 2024. More Info: $XBI $IBB $XPH $PPH

0

10

19

Ozmosi

@OzmosiHealth

5 months

$OCGN Ocugen completes dosing of subjects with Stargardt Disease in Phase 1/2 GARDian trial for OCU410ST gene therapy. More Info: $XBI $IBB $XPH $PPH

0

7

17

Ozmosi

@OzmosiHealth

1 year

Pharma/Biotech Highlights: $AGNPF: Algernon may spin off Ifenprodil development. $VRNA: Verona Pharma seeks FDA approval. $IMMP: Immutep receives patent for cancer treatment. $ACIU: FDA quickens development of Alzheimer's treatment.

3

1

17

Ozmosi

@OzmosiHealth

4 months

$OCGN Approval granted for Cohort 3 and Phase 2 enrollment in OCU410 ArMaDa study for Geographic Atrophy by Data and Safety Monitoring Board. More Info: $XBI $IBB $XPH $PPH

0

7

16

Ozmosi

@OzmosiHealth

11 months

$SAVA Enrollment for vital Phase 3 program of Simufilam in Alzheimer's disease completed by Cassava Sciences. More Info: $XBI $IBB $XPH $PPH

0

16

Ozmosi

@OzmosiHealth

6 months

$ESPR Esperion unveils significant new CLEAR Outcomes data at ACC.24, emphasizing NEXLETOL's value for various populations, including women, Hispanics, and obese patients. More Info: $XBI $IBB $XPH $PPH

1

5

14

Ozmosi

@OzmosiHealth

2 months

$OCGN Ocugen, Inc. finishes giving doses to subjects with geographic atrophy in high-dose group of Phase 1/2 ArMaDa trial for OCU410 gene therapy. More Info: $XBI $IBB $XPH $PPH

0

11

14

Ozmosi

@OzmosiHealth

6 months

$CYBN Cybin receives new US patent for CYB003, supporting its breakthrough therapy program for Major Depressive Disorder. More Info: $XBI $IBB $XPH $PPH

1

4

13

Ozmosi

@OzmosiHealth

1 year

$RVVTF Revive Therapeutics announces data safety monitoring board meeting date for Phase 3 clinical study of Bucillamine in the treatment of COVID-19. More Info: $XBI $IBB $XPH $PPH

0

3

12

Ozmosi

@OzmosiHealth

11 months

$RVVTF Revive Therapeutics updates on the development of a new formulation of Bucillamine. More Info: $XBI $IBB $XPH $PPH

1

4

12

Ozmosi

@OzmosiHealth

6 months

$OCGN Ocugen announces positive data and initiation of enrollment in medium dose for OCU410ST in GARDian study for Stargardt Disease. More Info: $XBI $IBB $XPH $PPH

0

7

11

Ozmosi

@OzmosiHealth

9 months

🚨 Upcoming Pharma/Biotech Catalysts Next 2 weeks 📅 👇 January 4th $STRO Luveltamab tazevibulin (Tumors) January 6th $ALT Pemvidutide (NASH) January 8th $AKTX Nomacopan (Autoimmune) $CLRB Iopofosine I 131 (Waldenstrom Macroglobulinemia) January 20ish $ANVS Buntanetap

2

11

Ozmosi

@OzmosiHealth

6 months

Cantargia releases preclinical findings on CAN10's potential in treating systemic sclerosis in top scientific journal. More Info: $XBI $IBB $XPH $PPH

0

1

11

Ozmosi

@OzmosiHealth

11 months

$CYBN Cybin to unveil Phase 2 results of CYB003's safety and efficacy in treating Major Depressive Disorder, along with an R&D briefing on Nov 30, 2023. More Info: $XBI $IBB $XPH $PPH

0

2

Ozmosi

@OzmosiHealth

1 year

$AGNPF Algernon Pharmaceuticals hires Maxim Group to investigate potential spin-off of its Ifenprodil Phase 2 chronic cough drug development program. More Info: $XBI $IBB $XPH $PPH

0

10

Ozmosi

@OzmosiHealth

9 months

🇺🇸PDUFA Dates January 2024🖊️ 1-3-2024 $CKPT Cosibelimab 1-5-2024 $NOVN Berdazimer sodium 1-12-2024 $ALPMY Zolbetuximab 1-17-2024 $MRK Belzutifan 1-20-2024 $MRK Keytruda 1-22-2024 $THTX Egrifta 1-23-2024 $HRTX HTX-011 1-24-2024 $LQDA Yutrepia 1-31-2024 $REGN Dupilumab

2

3

10

Ozmosi

@OzmosiHealth

8 months

$CANTA New data strengthens Cantargia's nadunolimab as a cancer combination therapy. More Info: $XBI $IBB $XPH $PPH

0

3

10

Ozmosi

@OzmosiHealth

6 months

$OCGN Ocugen, Inc. gets FDA clearance for IND Amendment to start OCU400 Phase 3 trial first gene therapy in Phase 3 for broad retinitis pigmentosa indication. More Info: $XBI $IBB $XPH $PPH

0

2

9

Ozmosi

@OzmosiHealth

1 year

$IPHA Innate Pharma to unveil latest interim phase 2 efficacy results of Lacutamab in Mycosis Fungoides at the prestigious International Conference on Malignant Lymphoma. More Info: $XBI $IBB $XPH $PPH

1

9

Ozmosi

@OzmosiHealth

8 months

$JAGX Jaguar Health has applied for Orphan Drug Designation from the FDA for Crofelemer, aiming to treat diarrhea caused by cholera. More Info: $XBI $IBB $XPH $PPH

4

2

7

Ozmosi

@OzmosiHealth

1 year

$RVVTF Revive Therapeutics shares Phase 3 Clinical Study update on Bucillamine for COVID-19 treatment. More Info: $XBI $IBB $XPH $PPH

0

9

Ozmosi

@OzmosiHealth

2 months

$OCGN Ocugen, Inc. completes dosing in subjects with geographic atrophy secondary to dAMD in high-dose cohort of OCU410 Phase 1/2 ArMaDa clinical trial—an innovative gene therapy. More Info: $XBI $IBB $XPH $PPH

0

5

8

Ozmosi

@OzmosiHealth

10 months

🇺🇸PDUFA Dates December 2023🖊️ 12-8-2023 $VRTX $CRSP Exagamglogene autotemcel $BCLI NurOwn 12-13-2023 $MIRM Livmarli 12-16-2023 $OPTN Xhance $MRK Pembrolizumab $ARQT Roflumilast $BMY $TSVT Abecma 12-20-2023 $BLUE Lovo-cel $CALT Nefecon 12-22-2023 $GKOS iDose® TR $IONS

0

3

9

Ozmosi

@OzmosiHealth

4 months

$ABUS Imdusiran in combination with Short Course Interferon successfully achieves sustained undetectable HBsAg levels, a critical step towards HBV Functional Cure. More Info: $XBI $IBB $XPH $PPH

0

1

9

Ozmosi

@OzmosiHealth

2 years

FDA announces Orphan Drug Designation for elamipretide by Stealth Bio to treat patients with Duchenne muscular dystrophy (DMD). $MITO is up more than 60% on the news 📈 #orphandrug #DMD #stocks

4

1

7

Ozmosi

@OzmosiHealth

1 year

$RVVTF Revive Therapeutics partners with Defence Research and Development Canada to assess Bucillamine for nerve agent impact. More Info: $XBI $IBB $XPH $PPH

0

4

8

Ozmosi

@OzmosiHealth

1 month

$OCGN Ocugen completes dosing for high dose cohort of Phase 1/2 GARDian trial for OCU410ST, a gene therapy for Stargardt Disease. More Info: $XBI $IBB $XPH $PPH

0

4

8

Ozmosi

@OzmosiHealth

9 months

$RVVTF Revive Therapeutics has successfully developed a new freeze-dried version of Bucillamine. More Info: $XBI $IBB $XPH $PPH

0

1

8

Ozmosi

@OzmosiHealth

1 year

$ARDX Ardelyx presents encouraging data on symptom response in IBS-C patients treated with IBSRELA® (tenapanor) and holds an IBS-C Product Theater at ACG 2023. More Info: $XBI $IBB $XPH $PPH

0

3

8

Ozmosi

@OzmosiHealth

8 months

$SGMO Sangamo Therapeutics gets FDA support for accelerated approval and EMA Prime eligibility of ST-920 in Fabry Disease. More Info: $XBI $IBB $XPH $PPH

0

1

8

Ozmosi

@OzmosiHealth

16 days

$TGTX Data for BRIUMVI® show 92% of patients with relapsing MS were free from disability progression after 5 years of treatment. More Info: $XBI $IBB $XPH $PPH

0

2

8

Ozmosi

@OzmosiHealth

4 months

$ADAP Adaptimmune will share data from mid-point analysis of IGNYTE-ESO trial at ASCO, showing support for Lete-cel and advancing sarcoma portfolio. More Info: $XBI $IBB $XPH $PPH

0

1

8

Ozmosi

@OzmosiHealth

1 year

$RVVTF Revive Therapeutics files patent for Bucillamine treating chemical warfare agent exposure. More Info: $XBI $IBB $XPH $PPH

0

1

8

Ozmosi

@OzmosiHealth

2 years

$MNMD up 45% today 🚀 as 20-year-old university student that made a $110 million profit with a one-month bet on Bed Bath & Beyond stock – also mentions Mind Medicine Mind Medicine also with positive updates on their pipeline this summer:

0

3

8

Ozmosi

@OzmosiHealth

7 months

$CANTA New human data from Cantargia supports CAN10 as a treatment for systemic sclerosis. More Info: $XBI $IBB $XPH $PPH

0

8

Ozmosi

@OzmosiHealth

1 month

$OCGN Ocugen gets approval from Health Canada to start Phase 3 trial of OCU400 for treating Retinitis Pigmentosa. More Info: $XBI $IBB $XPH $PPH

0

4

8

Ozmosi

@OzmosiHealth

10 months

$RVVTF Revive Therapeutics and Attwill Medical Solutions team up for clinical and commercial development of an innovative lyophilized version of Bucillamine. More Info: $XBI $IBB $XPH $PPH

0

1

8

Ozmosi

@OzmosiHealth

8 months

$BRTX BioRestorative Therapies will showcase early clinical data on BRTX-100 at the Orthopaedic Research Society (ORS) 2024 Annual Meeting. More Info: $XBI $IBB $XPH $PPH

1

2

7

Ozmosi

@OzmosiHealth

1 year

Pharma/Biotech Highlights: $NBIX: INGREZZA® provides stability. $CKPT: TILT cancer trial. $PXXLF: TWYMEEG (Imeglimin) sales reported. $ORTX: Orchard reports Q1, submits biologics license. $MRK: Collaboration for lung cancer testing. $TARA: Bladder cancer trial.

2

5

7

Ozmosi

@OzmosiHealth

9 months

Pharma/Biotech Highlights: $RVVTF: Revive innovates Bucillamine treatment for progress. $XERS: Xeris Biopharma obtains exclusive rights globally. $ACRS: Aclaris' trial for ATI-1777 successful. $EYPT: EyePoint Pharmaceuticals tests EYP-1901 for Macular Edema.

5

0

7

Ozmosi

@OzmosiHealth

6 months

$BNGO Bionano reports that optical genome mapping found 1250+ structural variants, including 56 gene fusions, in pediatric leukemia not detected by whole genome sequencing. More Info: $XBI $IBB $XPH $PPH

1

7

Ozmosi

@OzmosiHealth

7 months

$AQST Aquestive Therapeutics confirms successful pivotal study of Anaphylm™ (epinephrine) Sublingual Film meeting primary & secondary endpoints. FDA meeting results shared. More Info: $XBI $IBB $XPH $PPH

0

7

Ozmosi

@OzmosiHealth

1 year

$ARDX Ardelyx's Tenapanor takes a step towards addressing hyperphosphatemia as China accepts the new drug application. Promising news for patients in need! More Info: $XBI $IBB $XPH $PPH

0

7

Ozmosi

@OzmosiHealth

6 months

Cantargia shares data showing CAN10's potential in treating atherosclerosis. More Info: $XBI $IBB $XPH $PPH

0

1

7

Ozmosi

@OzmosiHealth

6 months

$OCGN Ocugen initiates enrollment in Phase 1/2 ArMaDa study for Geographic Atrophy, following positive data and safety monitoring board review for OCU410 modifier gene therapy. More Info: $XBI $IBB $XPH $PPH

0

1

6

Ozmosi

@OzmosiHealth

4 months

$MREO, RARE Ultragenyx and Mereo BioPharma report Phase 2 results from Orbit Study showing lasting decrease in fracture rates with Setrusumab (UX143) for Osteogenesis Imperfecta patients. More Info: $XBI $IBB $XPH $PPH

0

1

7

Ozmosi

@OzmosiHealth

8 months

$CGTX Patients with mild Alzheimer's disease who received continuous Simufilam treatment for 24 months showed no decline in cognition scores. More Info: $XBI $IBB $XPH $PPH

0

1

7

Ozmosi

@OzmosiHealth

1 year

$RVVTF: Safety Board Meeting. $PVTTF: Positive glomerulosclerosis study. $IMMP: Cancer treatment conference. $NRBO: FDA approves DA-1241 for NASH trial. $ANAB: Positive psoriasis treatment. $MBRX: Moleculin treats leukemia. $HZNP: Daxdilimab trials underway. $TARA: Protara tests

0

7

Ozmosi

@OzmosiHealth

6 months

New data from Cantargia reveals the interaction between CAN10 antibody and IL1RAP, leading to functional inhibition. More Info: $XBI $IBB $XPH $PPH

0

7

Ozmosi

@OzmosiHealth

8 months

$CANTA Cantargia receives US approval to begin Phase IIb trial for pancreatic cancer with Nadunolimab. More Info: $XBI $IBB $XPH $PPH

0

2

7

Ozmosi

@OzmosiHealth

2 months

🚨 UPCOMING CATALYST ANNOUNCED YESTERDAY !!📆 👇 $BNGO Optical Genome Mapping - Bionano Genomics (NASDAQ: BNGO) published a multi-site study in multiple myeloma (MM) comparing optical genome mapping (OGM) to cytogenetic methods for detecting structural variants (SVs).

0

1

7

Ozmosi

@OzmosiHealth

1 year

$VKTX Viking Therapeutics to present Phase 1 trial results of dual GLP-1/GIP receptor agonist VK2735 at ObesityWeek 2023. More Info: $XBI $IBB $XPH $PPH

0

3

6

Ozmosi

@OzmosiHealth

1 year

Alkeus announces $150M Series B financing to fast-track registration for gildeuretinol (ALK-001) in Stargardt Disease treatment. More Info: $XBI $IBB $XPH $PPH

0

3

7

Ozmosi

@OzmosiHealth

11 months

$ARDX Ardelyx announces that XPHOZAH® (tenapanor) is now accessible in the US. More Info: $XBI $IBB $XPH $PPH

0

7

Ozmosi

@OzmosiHealth

7 months

$MDGL FDA approves Madrigal Pharmaceuticals' Rezdiffra™ (resmetirom) for treating Noncirrhotic Nonalcoholic Steatohepatitis (NASH) with moderate to advanced liver fibrosis. More Info: $XBI $IBB $XPH $PPH

0

2

6

Ozmosi

@OzmosiHealth

1 year

$BEAM is down 25% in the past year, is there a catalyst event that can move it this year ?

6

1

6

Ozmosi

@OzmosiHealth

3 years

Beam Therapeutics hopes to 'transition to a clinical-stage company' with initiation of a P1 trial for their Sickle Cell Disease cell therapy 🧬 beam-101 in 2022 $BEAM is up 18% the past month 📈

1

2

6

Ozmosi

@OzmosiHealth

3 years

Mind Medicine finally gets a day not in the red as the FDA 🇺🇸 cleared its Investigational New Drug (IND) application which will allow the company to proceed with a Phase 2 trial of MM-120 for treatment of Generalized Anxiety Disorder (GAD) 🧠. $MNMD is up almost 17% today 📈.

0

5

Ozmosi

@OzmosiHealth

1 year

$VTYX Ventyx Biosciences' VTX-3232 enters Phase 1 trial as a promising CNS-Penetrant NLRP3 inhibitor More Info: $XBI $IBB $XPH $PPH

0

6

Ozmosi

@OzmosiHealth

3 years

Sorrento Therapeutics up ~13% today 📈 as they announced last week that their preclinical COVID-19 oral 💊 anti-viral sti-1558 effectively inhibited Omicron virus entry. A needed boost, since $SRNE has been down >50% over the last 3 months 📉. #COVID19 #antiviral

0

1

6

Ozmosi

@OzmosiHealth

1 year

$JAGX New research at Boston Children's Hospital demonstrates the possible use of Jaguar Health's Crofelemer in treating MVID, a rare disease in children. Harvard Medical School was involved in the study. More Info: $XBI $IBB $XPH $PPH

0

3

6

Ozmosi

@OzmosiHealth

1 year

$RVVTF Revive Therapeutics provides latest update on Phase 3 Clinical Study for Bucillamine in COVID-19 treatment. More Info: $XBI $IBB $XPH $PPH

0

1

6

Ozmosi

@OzmosiHealth

2 years

$MRNA vaccine MRNA-4157/V940 in combination with $MRK Keytruda MEETS PRIMARY EFFICACY ENDPOINT IN MELANOMA PHASE 2B KEYNOTE-942 TRIAL

bigmikehands

@bigmikehands

2 years

@OzmosiHealth $MRNA

0

1

0

1

6

Ozmosi

@OzmosiHealth

7 months

🧬 SPDR Biotech $XBI Movers Today 🩸 Top 3 XBI Gainers: $RCUS (Arcus Biosciences) 4.67% 📈 $EBS (Emergent) 8.25% 📈 $MRNA (Moderna) 8.88% 📈 Top 3 XBI Laggards: $VKTX (Viking Therapeutics) -11.1% 🔻 $MNKD (MannKind) -10.3% 🔻 $ARQT (Arcutis Bio) -9.5% 🔻

0

2

5

Ozmosi

@OzmosiHealth

2 years

Editas Medicine is up 37% in the past month 🔼 Earlier this week, $EDIT announced it had successfully dosed its first patient with their Sickle Cell Disease Gene Therapy EDIT301 🧬 in a P1 trial $CRISPR #stocks #biotech #genetherapy

0

2

6

Ozmosi

@OzmosiHealth

8 months

$IOVA Iovance's AMTAGVI™ (lifileucel) gets accelerated approval from FDA for advanced melanoma. More Info: $XBI $IBB $XPH $PPH

0

1

6

Ozmosi

@OzmosiHealth

9 months

$VINC Vincerx Pharma reports strong clinical effectiveness of Enitociclib combined with Venetoclax and Prednisone in treating Lymphoma. More Info: $XBI $IBB $XPH $PPH

0

1

4

Ozmosi

@OzmosiHealth

9 months

$HOTH: Hoth testing HT-001 on critically ill patients after FDA approval. $HALO $ARGX: Japan approves VYVDURA to treat Myasthenia Gravis. $PMVP: PMV Pharma advances trial and secures funding. $GHRS: GH Research secures patent for Mebufotenin.

0

1

Ozmosi

@OzmosiHealth

6 months

$XBI 🧬 down 11% the past month to ~ $83. Is this the bottom for 2024 ?

0

2

6

Ozmosi

@OzmosiHealth

1 year

$ARDX Ardelyx to provide updates on XPHOZAH (tenapanor) for Hyperphosphatemia at Kidney Week 2023, Nov 1-5 in Philadelphia, PA. More Info: $XBI $IBB $XPH $PPH

0

6

Ozmosi

@OzmosiHealth

6 months

$BDTX Black Diamond Therapeutics shares new data on EGFR mutations in NSCLC at AACR 2024, highlights potential for BDTX-1535. More Info: $XBI $IBB $XPH $PPH

0

2

6

Ozmosi

@OzmosiHealth

4 months

Cantargia shares Phase 2 Clinical Data for Nadunolimab in Pancreatic Cancer at ESMO Gastrointestinal Cancer Congress 2024. More Info: $XBI $IBB $XPH $PPH

0

3

6

Ozmosi

@OzmosiHealth

5 months

$KZIA Kazia completes Stage 1 of EVT801 Phase 1 trial in advanced cancer patients successfully. More Info: $XBI $IBB $XPH $PPH

0

1

6

Ozmosi

@OzmosiHealth

1 year

$KPTI Karyopharm's Selinexor granted FDA Fast Track designation for Myelofibrosis treatment, showing promising potential More Info: $XBI $IBB $XPH $PPH

0

3

6

Ozmosi

@OzmosiHealth

4 months

Progress continues in Cantargia's Phase 1 clinical trial for CAN10. More Info: $XBI $IBB $XPH $PPH

0

1

6

Ozmosi

@OzmosiHealth

19 days

$TNXP Tonix Pharmaceuticals has announced that its single-dose Mpox vaccine TNX-801 meets WHO's new Target Product Profile for Mpox vaccines in global health emergencies. More Info: $XBI $IBB $XPH $PPH

0

2

6

Ozmosi

@OzmosiHealth

3 years

FDA accepts Mirati Therapeutics new drug application (NDA) for their Lung Cancer Treatment adagrasib. $MRTX is down 20% the past week 📉. #oncology #FDA

0

1

5

Ozmosi

@OzmosiHealth

2 months

Transposon completes Phase 2 study of TPN-101 for C9orf72-related ALS and/or FTD with final results announced. More Info: $XBI $IBB $XPH $PPH

0

1

6

Ozmosi

@OzmosiHealth

1 year

$GERN Geron's Imetelstat presents promising results in IMerge Phase 3 trial showing durable transfusion independence in Lower Risk MDS patients at ASCO presentation More Info: $XBI $IBB $XPH $PPH

0

1

6

Ozmosi

@OzmosiHealth

9 months

$RVVTF Revive Therapeutics updates assessment of Bucillamine for nerve agent exposure with Defence Research and Development Canada. More Info: $XBI $IBB $XPH $PPH

0

3

6

Ozmosi

@OzmosiHealth

1 year

Pharma/Biotech Highlights: $ICPT: Intercept stock halted. $NBIX: Valbenazine treats Huntington's. $CADL: Candel's CAN-3110 shows glioma promise. $MRNA: Promising mRNA therapy. $TSHA $USM: Taysha presents promising data. $KT $KYMR: Kymera starts trial.

2

1

6

Ozmosi

@OzmosiHealth

11 months

$GILD Gilead and Arcus reveal positive results of Domvanalimab-based treatment for Upper GI Cancers, suggesting promising clinical activity in initial therapy. More Info: $XBI $IBB $XPH $PPH

0

2

5

Ozmosi

@OzmosiHealth

11 months

Pharma/Biotech Highlights: $RVVTF: Revive shares progress on Bucillamine improvements. $PHAR: Pharming tests leniolisib on young children. $IMUX: Immunic secures US patent for Vidofludimus. $BCRX: New Spanish treatment for hereditary angioedema.

3

2

6

Ozmosi

@OzmosiHealth

2 years

Today: $NTLA down 11% 🪦 $BEAM down 12% 😭 $CRSP down 10% ⚰️

Ozmosi

@OzmosiHealth

2 years

Past Week 🧬 Intellia Therapeutics $NTLA up 22% 📈 BEAM Therapeutics $BEAM up 17% 📈 CRISPR $CRSP up 25% 📈

0

1

4

1

2

6

Ozmosi

@OzmosiHealth

1 year

$LXRX Brand Institute collaborates with Lexicon Pharmaceuticals to develop brand name for FDA-approved INPEFA™ (sotagliflozin) More Info: $XBI $IBB $XPH $PPH

0

2

5

Ozmosi

@OzmosiHealth

3 years

Amylyx Pharma announces the FDA has scheduled a meeting with them to discuss clinical data & potential approval of their ALS drug AMX-0035. $AMLX is up 13% today 📈. #ALS #FDA

0

1

5

Ozmosi

@OzmosiHealth

2 years

NLS Pharmaceuticals announces positive results from their Phase 2 trial of Quilience 💊 to treat patients with Narcolepsy. $NLSP is down 24% today 📉 despite the results. #narcolepsy #stocks #pharma

1

3

5

Ozmosi

@OzmosiHealth

5 months

$IBRX ImmunityBio finishes GMP drug manufacturing for 170,000 ANKTIVA® doses. More Info: $XBI $IBB $XPH $PPH

0

5

Ozmosi

@OzmosiHealth

10 months

Kazia discloses non-binding letter of intent to grant rights for developing and commercializing Paxalisib beyond oncology. More Info: $XBI $IBB $XPH $PPH

0

1

4

Ozmosi

@OzmosiHealth

11 months

$PVCT New data on cancer immunotherapy PV-10 for metastatic uveal melanoma released by Provectus Biopharmaceuticals. More Info: $XBI $IBB $XPH $PPH

0

2

4

Ozmosi

@OzmosiHealth

2 years

Virios Therapeutics $VIRI crashes 70% 📉 as company announces their lead product IMC1 💊 failed to meet its Main Endpoint in a P2 Fibromyalgia study. #biotech #fail #stocks

0

5